Themis Medicare launches menopausal symptoms drug in India

Image
Capital Market
Last Updated : Jan 04 2023 | 12:04 PM IST

Themis Medicare announced that it has launched Lenzetto, a novel transdermal estradiol spray in the Indian market, for treatment of menopausal symptoms.

Lenzetto has been approved by United States Food and Drug Administration (USFDA) & European Medicines Agency (EMA) for the treatment of menopausal symptoms. Lenzetto is manufactured in Europe by Gedeon Richter.

According to Themis Medicare, Lenzetto is manufactured in and imported from Gedeon Richter, Hungary. Lenzetto will be available in a transdermal spray that facilitates 'metered dose application' on to small skin surface area in a unique easy to use packaging.

Dr. Sachin Patel, managing director & CEO of Themis Medicare said, Given the fact that gynecologists currently have limited treatment options for menopausal women, Lenzettoappears to offer a much needed therapeutic option to gynecologists for treating menopausal symptoms in women with immense clinical benefit and convenience.

Lenzetto will provide convenience to women as it is transdermal spray that menopausal women can just 'spray and go' unlike currently available transdermal gel which are inconvenient and messy to apply. Lenzetto will be promoted by a task force which will be exclusively meeting gynecologists across the country.

Themis Medicare is a pharma company specializing in the development of complex molecules. It has a diversified business model with presence across the B2B model and strong presence in domestic B2C market. The company also has a significant export presence in the RoW geographies.

On a consolidated basis, net profit of Themis Medicare declined 7.8% to Rs 17.78 crore on 15.3% decrease in net sales to Rs 91 crore in Q2 FY23 over Q2 FY22.

The scrip rose 0.52% to currently trade at Rs 1,356.35 on the BSE.

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Jan 04 2023 | 11:57 AM IST

Next Story